Alprolix company?

See the DrugPatentWatch profile for Alprolix

Alprolix is manufactured by-[(1)] Baxalta US Inc., which is now a subsidiary of Takeda Pharmaceutical Company Limited-[(2)].

What is Alprolix used for?

Alprolix is a recombinant factor IX Fc fusion protein used for the treatment of hemophilia B-[(1)]. It helps to reduce the frequency of bleeding episodes in individuals with this condition-[(1)].

How does Alprolix work?

The drug is designed to extend the half-life of factor IX in the bloodstream, meaning it stays in the body longer than traditional factor IX therapies-[(2)]. This allows for less frequent dosing-[(1)].

When did Alprolix patents expire?

Information on Alprolix's patent expiration can be found on DrugPatentWatch.com-[(3)]. Patent expiry dates are crucial for understanding when generic or biosimilar versions of a drug may become available, potentially impacting pricing and market competition-[(3)].

Who are Alprolix's competitors?

Other treatments for hemophilia B include other recombinant factor IX products and plasma-derived factor IX concentrates. The development of extended half-life factor products has intensified competition in the hemophilia treatment market-[(2)].